Microviable Therapeutics (MVT) is a Spanish biotechnology SME developing novel microbiota-based biological medicines to improve human health. The company combines expertise in anaerobic microbiology, live biotherapeutic product development, microbiome bioinformatics, and translational microbiome research.
MVT's core capabilities include the isolation, cultivation, characterization, stabilization, and lyophilization of gut bacterial strains, including strict anaerobes, as well as microbiome profiling through advanced bioinformatic analyses. These activities are supported by the proprietary PharmaBiota® platform, which comprises a collection of more than 2,000 bacterial isolates from over 170 species, enabling the identification of novel therapeutic candidates and the rational design of bacterial consortia for specific medical applications.
A key strength of MVT is its ability to preserve, manipulate, and process complex gut microbial communities while maintaining the viability and diversity of highly oxygen-sensitive microorganisms. This expertise is exemplified by GutAlive®, an IVDR-certified technology for anaerobic microbiota sampling and transport that preserves the original microbial composition and viability of strict anaerobes, reflecting MVT's broader capabilities in microbiome-based product development.
MVT focuses on diseases and physiological conditions in which the microbiota plays a modulating role, with particular emphasis on infectious diseases and oncology. The company seeks to participate in collaborative R&D projects addressing microbiome-based interventions, antimicrobial resistance (AMR), cancer, immunotherapy, treatment toxicity management, and related areas.
As a consortium partner, MVT can contribute across the microbiome R&D pipeline, from microbiota sampling, strain isolation, cultivation, characterization, and bioinformatic analysis to bacterial consortium design and the development of live biotherapeutic products, supporting the translation of microbiome science into innovative and scalable therapeutic solutions.